Fate Therapeutics Inc (FATE) stock
Close on Nov 11, 2026Market cap $192.31MP/E –Yield –
Fate Therapeutics Inc saw revenue fall 33.4% to $4.75M over the twelve months to Sep 30, 2026. Free cash flow was -$106.85M. At the latest close the market valued the company at $192.31M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $192.31M
- P/E ratio
- –
- Price to sales
- 40.49
- Price to book
- 1.45
- Dividend yield
- –
- Free cash flow yield
- -55.56%
Fundamentals
- Revenue
- $4.75M
- Net income
- -$124.43M
- EPS, diluted
- -$1.03
- Free cash flow
- -$106.85M
- Book value per share
- $1.08
- Diluted shares
- 124M
Trading
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Previous close
- $1.77
- Open
- $1.78
- Day's range
- $1.60 – $1.79
- Volume
- 2,650,080
- Average volume (20 days)
- 1,436,186
- Beta (5 years)
- 2.46
- 52-week range
- $0.95 – $3.23
- RSI (14 days)
- 30.6
- Volatility (1 year)
- 89.5%
- Relative volume
- 1.52×
- WACC
- 17.2%
Market cap history
Month-end market cap since 2013, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | FATE | S&P 500 | Difference | FATE per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -26.4% | -2.4% | −24.0 pts | ||
| 3 months | -41.4% | -1.2% | −40.3 pts | ||
| Year to date | +63.3% | +12.3% | +51.0 pts | ||
| 1 year | +43.3% | +12.4% | +30.9 pts | ||
| 3 years | -22.1% | +78.8% | −100.9 pts | -8.0% | +21.4% |
| 5 years | -97.2% | +75.2% | −172.3 pts | -50.9% | +11.9% |
| 10 years | -45.2% | +311.1% | −356.3 pts | -5.8% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Fate Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Results
- News
- Results
- Results
About Fate Therapeutics
Biological Products, (No Diagnostic Substances)
The company is a clinical-stage biopharmaceutical firm that develops off-the-shelf cellular immunotherapies using human induced pluripotent stem cells. Through cellular programming and multiplex engineering, it generates master cell lines to mass-produce uniform chimeric antigen receptor T-cell and natural killer cell therapies. Its principal product candidates include FT819, FT522, FT825, FT836, and FT839, which are designed to treat autoimmune disorders such as systemic lupus erythematosus, systemic sclerosis, vasculitis, and myositis, alongside advanced solid tumors. Its end users are patients with severe cancers and autoimmune conditions.
Company profile, executives and historyFate Therapeutics stock: common questions
What is Fate Therapeutics's stock price?
FATE closed at $1.60 on Nov 11, 2026, down 9.32% on the day. Over the past 52 weeks it traded between $0.95 and $3.23.
What is Fate Therapeutics's market cap?
Fate Therapeutics was worth $192.31M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is FATE's P/E ratio?
Fate Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.03), so it has no meaningful P/E ratio.
How much revenue does Fate Therapeutics make?
Fate Therapeutics reported revenue of $4.75M for the twelve months to Sep 30, 2026, down 33.4% from a year earlier.
Does Fate Therapeutics pay a dividend?
No. Fate Therapeutics has not paid a cash dividend over the last twelve months.
When does Fate Therapeutics report earnings next?
Fate Therapeutics is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has FATE stock performed over the past year?
Including dividends, FATE returned +43.3% over the past year, against +12.4% for the S&P 500.
How many FATE shares are sold short?
10M shares were sold short at the latest FINRA report, 11.20% of the float, or 8.3 days of average trading volume.
Who are Fate Therapeutics's competitors?
Companies most similar to Fate Therapeutics by business, industry and size include TCRX, ATRA, CRBU, LCTX, IPHA.
See a number that looks wrong?